Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 24;25(19):10272.
doi: 10.3390/ijms251910272.

Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer

Rafał Watrowski  1   2 , Eva Schuster  3 , Toon Van Gorp  4   5 , Gerda Hofstetter  6 , Michael B Fischer  7   8 , Sven Mahner  9   10 , Stefan Polterauer  3 , Robert Zeillinger  3 , Eva Obermayr  3
Affiliations

Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer

Rafał Watrowski et al. Int J Mol Sci. .

Abstract

Single nucleotide polymorphisms (SNPs) of the IL-16 gene have been reported to influence the risk of several cancers, but their role in ovarian cancer (OC) has not been studied. Using the restriction fragment length polymorphism (PCR-RFLP) method, we examined four IL-16 SNPs: rs11556218 (T > G), rs4778889 (T > C), rs4072111 (C > T), and rs1131445 (T > C) in blood samples from 413 women of Central European descent, including 200 OC patients and 213 healthy controls. Among the patients, 62% were postmenopausal, 84.5% were diagnosed in late stages (FIGO IIb-IV), and 73.5% had high-grade serous OC (HGSOC). Minor allele frequencies in controls were 9.2% for rs11556218 (G allele), 13.7% for rs4778889 (C allele), 10.4% for rs4072111 (T allele), and 32.3% for rs1131445 (C allele). We found significant associations of rs11556218 (G vs. T allele: OR 2.76, 95% CI 1.84-4.14, p < 0.0001) with elevated OC risk in the whole cohort (p < 0.001) and in both premenopausal (p < 0.001) and postmenopausal (p = 0.001) subgroups. These associations remained significant across heterozygote (p < 0.001), dominant (p < 0.001), and overdominant (p < 0.001) models. IL-16 rs4778889 was associated with OC risk predominantly in premenopausal women (p < 0.0001 in almost all models). In the whole cohort, the C allele was associated with OC risk (OR 1.54, CI 95% 1.06-2.23, p = 0.024), and the association of rs4778889 was significant in dominant (p = 0.019), overdominant (p = 0.033), and heterozygote (p = 0.027) models. Furthermore, rs4778889 was linked with HGSOC (p = 0.036) and endometriosis-related OC subtypes (p = 0.002). No significant associations were found for rs4072111 or rs1131445 (p = 0.81 or 0.47, respectively). In conclusion, rs11556218 and rs4778889 SNPs are associated with OC risk, especially in premenopausal women.

Keywords: IL-16; cancer risk; interleukin-16; ovarian cancer; premenopausal cancer; single nuclear polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure A1
Figure A1
Age at initial diagnosis in cases and controls.
Figure A2
Figure A2
Menopausal status (cutoff point 51 years) of cases and controls.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Zhou Z., Wang X., Ren X., Zhou L., Wang N., Kang H. Disease Burden and Attributable Risk Factors of Ovarian Cancer From 1990 to 2017: Findings from the Global Burden of Disease Study 2017. Front. Public Health. 2021;9:619581. doi: 10.3389/fpubh.2021.619581. - DOI - PMC - PubMed
    1. Marth C., Abreu M.H., Andersen K.K., Aro K.M., de Lurdes Batarda M., Boll D., Ekmann-Gade A.W., Haltia U.-M., Hansen J., Haug A.J., et al. Real-Life Data on Treatment and Outcomes in Advanced Ovarian Cancer: An Observational, Multinational Cohort Study (RESPONSE Trial) Cancer. 2022;128:3080–3089. doi: 10.1002/cncr.34350. - DOI - PMC - PubMed
    1. McCluggage W.G. Morphological Subtypes of Ovarian Carcinoma: A Review with Emphasis on New Developments and Pathogenesis. Pathology. 2011;43:420–432. doi: 10.1097/PAT.0b013e328348a6e7. - DOI - PubMed
    1. Köbel M., Kang E.Y. The Evolution of Ovarian Carcinoma Subclassification. Cancers. 2022;14:416. doi: 10.3390/cancers14020416. - DOI - PMC - PubMed

LinkOut - more resources